6 O
ADVERSE O
REACTIONS O
Because O
clinical O
studies O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
studies O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

EXCERPT O
: O
Most O
common O
adverse O
reactions O
associated O
with O
the O
use O
of O
SURFAXIN O
are O
endotracheal O
tube O
reflux O
, O
pallor O
, O
endotracheal O
tube O
obstruction O
, O
and O
need O
for O
dose O
interruption O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Discovery O
Laboratories O
, O
Inc O
. O
at O
1-877-SURFAXN O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Studies O
in O
Premature O
Infants O
at O
Risk O
for O
Respiratory O
Distress O
Syndrome O
The O
safety O
data O
described O
below O
reflect O
exposure O
to O
SURFAXIN O
at O
a O
dose O
of O
5.8 O
mL O
per O
kg O
( O
up O
to O
4 O
doses O
) O
administered O
in O
either O
4 O
aliquots O
( O
Study O
1 O
) O
or O
2 O
aliquots O
( O
Study O
2 O
) O
in O
643 O
infants O
32 O
weeks O
gestational O
age O
or O
less O
in O
2 O
randomized O
double-blind O
, O
active-controlled O
clinical O
studies O
in O
which O
infants O
could O
receive O
up O
to O
4 O
doses O
of O
surfactant O
intratracheally O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

Study O
1 O
was O
conducted O
in O
1294 O
premature B-Not_AE_Candidate
infants I-Not_AE_Candidate
who O
weighed O
between O
600 O
g O
and O
1250 O
g O
at O
birth O
and O
were O
32 O
weeks O
or O
less O
in O
gestational O
age O
. O

Infants O
received O
1 O
of O
3 O
surfactants O
, O
SURFAXIN O
( O
N O
= O
524 O
) O
, O
colfosceril O
palmitate O
( O
N O
= O
506 O
) O
, O
or O
beractant O
( O
N O
= O
258 O
) O
. O

Study O
2 O
was O
conducted O
in O
252 O
premature B-Not_AE_Candidate
infants I-Not_AE_Candidate
who O
weighed O
between O
600 O
g O
and O
1250 O
g O
and O
were O
less O
than O
29 O
weeks O
in O
gestational O
age O
. O

Infants O
received O
SURFAXIN O
( O
N O
= O
119 O
) O
or O
poractant O
alfa O
( O
N O
= O
124 O
) O
. O

Comparator O
surfactants O
colfosceril O
palmitate O
and O
beractant O
were O
administered O
at O
the O
recommended O
doses O
( O
5.0 O
and O
4.0 O
mL O
per O
kg O
, O
respectively O
) O
while O
the O
first O
dose O
of O
poractant O
alfa O
administered O
( O
2.2 O
mL O
per O
kg O
) O
was O
less O
than O
the O
recommended O
dose O
of O
2.5 O
mL O
per O
kg O
. O

Any O
subsequent O
doses O
of O
poractant O
alfa O
were O
at O
the O
recommended O
1.25 O
mL O
per O
kg O
dose O
. O

Administration B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
( O
endotracheal B-OSE_Labeled_AE
tube I-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
, O
pallor B-OSE_Labeled_AE
, O
endotracheal B-OSE_Labeled_AE
tube I-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
and O
need O
for O
dose O
interruption O
) O
were O
assessed O
in O
both O
SURFAXIN O
controlled O
clinical O
studies O
. O

Overall O
, O
the O
incidence O
of O
administration B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
was O
higher O
in O
infants O
who O
received O
SURFAXIN O
compared O
to O
other O
surfactants O
( O
Table O
2 O
) O
and O
resulted O
in O
a O
greater O
proportion O
of O
infants O
treated O
with O
SURFAXIN O
who O
experienced O
administration B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
oxygen O
desaturation O
an B-OSE_Labeled_AE
d O
bradycar I-OSE_Labeled_AE
d I-OSE_Labeled_AE
i I-OSE_Labeled_AE
a I-OSE_Labeled_AE
. O

For O
Study O
1 O
, O
oxygen B-OSE_Labeled_AE
desaturation I-OSE_Labeled_AE
was O
reported O
in O
17 O
% O
, O
9 O
% O
, O
and O
13 O
% O
and O
bradycardia B-OSE_Labeled_AE
for O
5 O
% O
, O
2 O
% O
, O
and O
3 O
% O
of O
infants O
treated O
with O
SURFAXIN O
, O
colfosceril O
palmitate O
, O
and O
beractant O
, O
respectively O
. O

For O
Study O
2 O
, O
oxygen B-OSE_Labeled_AE
desaturation I-OSE_Labeled_AE
was O
reported O
in O
8 O
% O
and O
2 O
% O
and O
bradycardia B-OSE_Labeled_AE
in O
3 O
% O
and O
2 O
% O
of O
infants O
treated O
with O
SURFAXIN O
and O
poractant O
alfa O
, O
respectively O
. O

These O
adverse O
reactions O
did O
not O
appear O
to O
be O
associated O
with O
an O
increased O
incidence O
of O
serious O
complications O
or O
mortality O
relative O
to O
the O
comparator O
surfactants O
( O
Table O
3 O
) O
. O

Table O
2 O
. O

Administration-Related O
Adverse O
Reactions O
in O
SURFAXIN O
Controlled O
Clinical O
Studies O
a O
a O
Table O
includes O
only O
infants O
who O
received O
study O
treatment O
. O

b O
In O
Study O
1 O
doses O
were O
administered O
in O
4 O
aliquots O
. O

c O
In O
Study O
2 O
doses O
were O
administered O
in O
2 O
aliquots O
. O

Study O
1 O
b O
Study O
2 O
c O
SURFAXIN O
( O
N O
= O
524 O
) O
Colfoscerilpalmitate O
( O
N O
= O
506 O
) O
Beractant O
( O
N O
= O
258 O
) O
SURFAXIN O
( O
N O
= O
119 O
) O
Poractant O
alfa O
( O
N O
= O
124 O
) O
Total O
DosesAdministered O
994 O
1038 O
444 O
174 O
160 O
Total O
Number O
of O
Events O
( O
Events O
per O
100 O
Doses O
) O
ETT B-OSE_Labeled_AE
Reflux I-OSE_Labeled_AE
183 O
( O
18 O
) O
161 O
( O
16 O
) O
67 O
( O
15 O
) O
47 O
( O
27 O
) O
31 O
( O
19 O
) O
Pallor B-OSE_Labeled_AE
88 O
( O
9 O
) O
46 O
( O
4 O
) O
38 O
( O
9 O
) O
18 O
( O
10 O
) O
7 O
( O
4 O
) O
Dose B-OSE_Labeled_AE
Interruption I-OSE_Labeled_AE
87 O
( O
9 O
) O
46 O
( O
4 O
) O
30 O
( O
7 O
) O
7 O
( O
4 O
) O
2 O
( O
1 O
) O
ETT B-OSE_Labeled_AE
Obstruction I-OSE_Labeled_AE
55 O
( O
6 O
) O
21 O
( O
2 O
) O
19 O
( O
4 O
) O
27 O
( O
16 O
) O
1 O
( O
1 O
) O
Table O
3 O
. O

Common O
Serious O
Complications O
Associated O
with O
Prematurity O
and O
RDS O
in O
SURFAXIN O
Controlled O
Clinical O
Studies O
Through O
36-Weeks O
Post-Conceptual O
Age O
( O
PCA O
) O
Study O
1 O
Study O
2 O
SURFAXIN O
( O
N O
= O
527 O
) O
% O
Colfoscerilpalmitate O
( O
N O
= O
509 O
) O
% O
Beractant O
( O
N O
= O
258 O
) O
% O
SURFAXIN O
( O
N O
= O
119 O
) O
% O
Poractantalfa O
( O
N O
= O
124 O
) O
% O
Apnea B-Not_AE_Candidate
52 O
52 O
46 O
66 O
75 O
Intraventricular B-Not_AE_Candidate
hemorrhage I-Not_AE_Candidate
, O
all O
grades O
52 O
57 O
54 O
39 O
38 O
- O
Grade O
3/4 O
19 O
18 O
21 O
13 O
8 O
Periventricular B-Not_AE_Candidate
leukomalacia I-Not_AE_Candidate
10 O
10 O
12 O
4 O
9 O
Acquired O
sepsis B-Not_AE_Candidate
44 O
44 O
44 O
45 O
52 O
Patent B-Not_AE_Candidate
ductus I-Not_AE_Candidate
arteriosus I-Not_AE_Candidate
37 O
35 O
37 O
43 O
44 O
Retinopathy B-Not_AE_Candidate
of I-Not_AE_Candidate
prematurity I-Not_AE_Candidate
, O
all O
grades O
27 O
26 O
25 O
32 O
31 O
-Grade O
3/4 O
6 O
7 O
6 O
5 O
9 O
Necrotizing B-Not_AE_Candidate
enterocolitis I-Not_AE_Candidate
, O
all O
grades O
17 O
17 O
19 O
13 O
15 O
-Grade O
2/3 O
6 O
8 O
14 O
8 O
8 O
Pulmonary B-Not_AE_Candidate
air I-Not_AE_Candidate
leak I-Not_AE_Candidate
through O
Day O
7 O
, O
all O
types O
15 O
17 O
14 O
9 O
7 O
- O
Pulmonary B-Not_AE_Candidate
interstitial I-Not_AE_Candidate
emphysema I-Not_AE_Candidate
9 O
10 O
10 O
3 O
5 O
- O
Pneumothorax B-Not_AE_Candidate
3 O
4 O
2 O
4 O
1 O
Pulmonary B-Not_AE_Candidate
hemorrhage I-Not_AE_Candidate
10 O
12 O
14 O
6 O
9 O
All-cause O
mortality O
through O
36-weeks O
PCA O
was O
similar O
regardless O
of O
which O
exogenous O
surfactant O
was O
administered O
. O

Adverse O
reactions O
reported O
in O
the O
controlled O
clinical O
studies O
through O
36-weeks O
PCA O
occurring O
in O
at O
least O
10 O
% O
of O
infants O
were O
anemia B-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
metabolic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
, O
oxygen B-OSE_Labeled_AE
desaturation I-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
, O
and O
bradycardia B-OSE_Labeled_AE
. O

These O
reactions O
occurred O
at O
rates O
similar O
to O
the O
comparator O
surfactants O
. O

No O
assessments O
for O
immunogenicity O
to O
SURFAXIN O
were O
performed O
in O
these O
clinical O
studies O
. O

Follow-up O
Evaluations O
Twelve-month O
corrected-age O
follow-up O
of O
1546 O
infants O
enrolled O
in O
the O
2 O
controlled O
clinical O
studies O
demonstrated O
no O
significant O
differences O
in O
mortality O
or O
gross O
neurologic O
findings O
between O
infants O
treated O
with O
SURFAXIN O
and O
those O
treated O
with O
the O
comparator O
surfactants O
( O
colfosceril O
palmitate O
, O
beractant O
, O
or O
poractant O
alfa O
) O
. O

Clinical O
Study O
in O
Adults O
with O
ARDS O
The O
safety O
and O
efficacy O
of O
lucinactant O
administered O
in O
2 O
doses O
separated O
by O
48 O
hours O
via O
segmental O
bronchoscopic O
lavage O
in O
adults O
with O
ARDS B-Not_AE_Candidate
was O
evaluated O
in O
a O
two-part O
clinical O
trial O
in O
124 O
adult O
patients O
. O

Twenty-two O
patients O
were O
studied O
in O
the O
initial O
open-label O
portion O
of O
the O
trial O
( O
Part O
A O
) O
and O
102 O
patients O
participated O
in O
a O
subsequent O
randomized O
controlled O
portion O
( O
Part O
B O
) O
. O

Compared O
to O
standard O
of O
care O
, O
patients O
who O
received O
treatment O
with O
lucinactant O
via O
segmental O
bronchoscopic O
lavage O
at O
doses O
up O
to O
50 O
mL O
per O
lung O
segment O
had O
an O
increased O
incidence O
of O
death B-NonOSE_AE
, O
multi B-NonOSE_AE
- I-NonOSE_AE
organ I-NonOSE_AE
failure I-NonOSE_AE
, O
sepsis B-NonOSE_AE
, O
anoxic B-NonOSE_AE
encephalopathy I-NonOSE_AE
, O
renal B-NonOSE_AE
failure I-NonOSE_AE
, O
hypoxia B-NonOSE_AE
/ O
decreased B-NonOSE_AE
oxygen I-NonOSE_AE
saturation I-NonOSE_AE
, O
pneumothorax B-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
and O
pulmonary B-NonOSE_AE
embolism I-NonOSE_AE
compared O
to O
those O
patients O
receiving O
standard O
of O
care O
. O

SURFAXIN O
is O
not O
indicated O
for O
use O
in O
the O
treatment O
of O
ARDS B-Not_AE_Candidate
. O

